VISTARA BIOSCIENCE

Vistara's TRIFECTA strategy is at the intersection of the innate degradation mechanism of the clinical target, the molecules which alter its degradation, and solutions which can be created for clinical applications... Then we design solutions for targeted disruption of the candidate using insights gained from holistic views of the ubiquitome, crosstalk with biological pathways, and small molecule discovery... We are expanding the knowledgebase of E3 ligase degrome signatures and crosstalk with other pathways for modeling biological decision-making.

Also known as: VISTARA